Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway
Metrics: PDF 3210 views | HTML 3428 views | ?
Harish Potu1, Luke F. Peterson1, Anupama Pal1, Monique Verhaegen2, Juxiang Cao3, Moshe Talpaz1 and Nicholas J. Donato1
1 Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
2 Department of Dermatology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI
3 Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts
Nicholas J. Donato, email:
Keywords: Usp5, ubiquitination, BRAF, p53, FAS, melanoma
Received: April 28, 2014 Accepted: June 24, 2014 Published: June 26, 2014
Usp5 is a deubiquitinase (DUB) previously shown to regulate unanchored poly-ubiquitin (Ub) chains, p53 transcriptional activity and double-strand DNA repair. In BRAF mutant melanoma cells, Usp5 activity was suppressed by BRAF inhibitor (vemurafenib) in sensitive but not in acquired or intrinsically resistant cells. Usp5 knockdown overcame acquired vemurafenib resistance and sensitized BRAF and NRAS mutant melanoma cells to apoptosis initiated by MEK inhibitor, cytokines or DNA-damaging agents. Knockdown and overexpression studies demonstrated that Usp5 regulates p53 (and p73) levels and alters cell growth and cell cycle distribution associated with p21 induction. Usp5 also regulates the intrinsic apoptotic pathway by modulating p53-dependent FAS expression. A small molecule DUB inhibitor (EOAI3402143) phenocopied the FAS induction and apoptotic sensitization of Usp5 knockdown and fully blocked melanoma tumor growth in mice. Overall, our results demonstrate that BRAF activates Usp5 to suppress cell cycle checkpoint control and apoptosis by blocking p53 and FAS induction; all of which can be restored by small molecule-mediated Usp5 inhibition. These results suggest that Usp5 inhibition can provide an alternate approach in recovery of diminished p53 (or p73) function in melanoma and can add to the targeted therapies already used in the treatment of melanoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.